KTTA · Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp (KTTA)
What's happening
- KTTA is up 20.70% today, trading at $0.49. — Live quote
- Volume today (11,325) is well below its 3-month average of 534,100. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.16 actual vs. $-0.16 estimated (+2.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $16.9M | $17.9M | $42.7M | $32.4M | $23.5M |
| P/E | -1.14 | -1.36 | -3.20 | -2.29 | -1.65 |
| Price/Book | 0.34 | 0.33 | 3.50 | 2.14 | 1.81 |
| ROE | -29.89% | -24.06% | -109.09% | -93.19% | -110.10% |
| ROA | -28.81% | -23.40% | -97.70% | -83.16% | -97.48% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -6478.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -45.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on KTTA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.7M | -$4.9M | -$3.1M | -$3.8M | -$3.7M | -$3.0M | -$3.9M | -$4.0M |
| Net income | -$5.3M | -$2.9M | -$3.0M | -$3.7M | -$3.6M | -$3.0M | -$3.9M | -$3.9M |
| EPS (diluted) | $-0.16 | $-0.12 | $-0.41 | $-0.66 | $-1.61 | $-2.87 | $-3.71 | $-3.70 |
| EPS (basic) | $-0.16 | $-0.12 | $-0.41 | $-0.66 | $-1.61 | $-2.87 | $-3.71 | $-3.70 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Jan '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $51.7M | $56.4M | $60.2M | $13.6M | $17.0M | $14.7M | — | $16.1M |
| Total liabilities | $1.9M | $1.5M | $5.0M | $1.4M | $1.8M | $1.7M | — | $1.3M |
| Stockholders' equity | $49.8M | $54.8M | $55.2M | $12.2M | $15.2M | $13.0M | $14.8M | $14.8M |
| Total current assets | $48.2M | $52.7M | $56.5M | $5.5M | $8.6M | $6.1M | — | $7.4M |
| Total current liabilities | $1.8M | $1.5M | $5.0M | $1.4M | $1.7M | $1.6M | — | $1.1M |
| Cash & equivalents | $45.7M | $50.4M | $55.2M | $4.1M | $7.2M | $5.3M | — | $6.9M |
| Other current assets | $22.5K | $400.5K | $387.8K | $19.7K | $117.8K | $162.5K | — | $142.9K |
| Property, plant & equipment | — | — | — | — | $113.6K | $117.5K | — | $122.3K |
| Goodwill | — | — | — | $1.3M | $1.3M | $1.3M | — | $1.3M |
| Intangible assets | $3.5M | $3.6M | $3.8M | $3.9M | $4.1M | $4.3M | — | $7.3M |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $3.3K | $2.5K | $2.3K | $743 | $743 | $270 | — | $139 |
| Retained earnings | -$78.2M | -$72.9M | -$70.0M | -$59.9M | -$56.9M | -$53.1M | — | -$49.6M |
| Accumulated other comprehensive income (loss) | $9.6K | $46.9K | $18.8K | $18.3K | $5.6K | — | — | -$7.2K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.7M | -$4.8M | -$5.4M | -$2.9M | -$3.9M | -$3.1M | -$2.4M | -$3.1M |
| Investing cash flow | — | — | $11.0K | — | — | — | — | — |
| Financing cash flow | $8.5K | $750 | $56.4M | -$116.1K | $5.7M | $1.5M | -$23.6K | $4.5M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $329.9K | $139.2K | $88.3K | $53.0K | $57.6K | $98.6K | $118.4K | $147.9K |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $486.6K | $15.1K |
| Gross profit | — | — | — | — | -$2.2K |
| Operating income | -$20.9M | -$14.2M | -$16.0M | -$12.6M | -$4.5M |
| Net income | -$20.4M | -$13.9M | -$16.0M | -$13.9M | -$2.2M |
| EPS (diluted) | $-2.91 | $-12.69 | $-0.42 | $-1.76 | $-0.21 |
| EPS (basic) | $-2.91 | $-12.69 | $-0.42 | $-1.76 | $-0.21 |
| Operating margin | — | — | — | -$2.6K | -$29.9K |
| Net margin | — | — | — | -$2.9K | -$14.4K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M |
| Stockholders' equity | $55.2M | $14.8M | $23.4M | $42.5M | $51.4M |
| Total current assets | $56.5M | $7.4M | $16.7M | $34.1M | $53.3M |
| Total current liabilities | $5.0M | $1.1M | $2.6M | $1.9M | $447.3K |
| Cash & equivalents | $55.2M | $6.9M | $16.3M | $33.1M | $53.0M |
| Other current assets | $387.8K | $142.9K | $104.7K | $263.0K | — |
| Property, plant & equipment | — | $122.3K | $141.2K | $125.2K | $20.1K |
| Goodwill | — | $1.3M | $1.3M | $1.3M | — |
| Intangible assets | $3.8M | $7.3M | $5.0M | — | — |
| Common stock & paid-in capital | $2.3K | $139 | $104 | $130 | $17.7K |
| Retained earnings | -$70.0M | -$49.6M | -$35.3M | -$19.4M | -$2.2M |
| Accumulated other comprehensive income (loss) | $18.8K | -$7.2K | -$4.7K | -$661 | -$10.6K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$15.2M | -$13.9M | — | -$14.6M | -$3.2M |
| Investing cash flow | $11.0K | — | — | -$2.1M | -$21.5K |
| Financing cash flow | $63.5M | $4.5M | — | -$3.2M | $55.9M |
| Free cash flow | — | — | — | -$14.7M | -$3.2M |
| Capital expenditures | — | — | $34.3K | $107.1K | $21.5K |
| Share-based compensation | $297.5K | $773.7K | $592.3K | $835.1K | $471.2K |
| Share repurchases | — | — | $3.7M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding KTTA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-06-12 to 2026-06-17
Recent transactions
- Insiders have net bought 100,000 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: Coastlands Capital LP (10% owner) — Open market purchase of 100,000 shares on 2026-06-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Coastlands Capital LP | 10% owner | Open market purchase | 2026-06-17 | 100,000 |
| STEINMAN LAWRENCE | Director | Open market purchase | 2025-11-28 | 133,333 |
| Schneiderman Daniel H | Chief Financial Officer | Grant / award | 2025-11-28 | 26,667 |
| Marques Tiago | Chief Executive Officer | Open market purchase | 2025-11-28 | 33,333 |
| Dumesnil Simon | Director | Open market purchase | 2025-11-28 | 33,333 |
| Leahy Emer | Director | Grant / award | 2025-11-28 | 33,333 |
| Novak Alfred J | Director | Grant / award | 2024-06-13 | 2,750 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-17 | Coastlands Capital LP | 10% owner | Open market purchase | 100,000 | $0.53 |
| 2025-11-28 | STEINMAN LAWRENCE | Director | Open market purchase | 133,333 | $0.75 |
| 2025-11-28 | Schneiderman Daniel H | Chief Financial Officer | Grant / award | 26,667 | $0.75 |
| 2025-11-28 | Marques Tiago | Chief Executive Officer | Open market purchase | 33,333 | $0.75 |
| 2025-11-28 | Dumesnil Simon | Director | Open market purchase | 33,333 | $0.75 |
| 2025-11-28 | Leahy Emer | Director | Grant / award | 33,333 | $0.75 |
| 2025-05-12 | Marques Tiago | Chief Executive Officer | Open market sale | 960 | $0.82 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:33 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-16 | 8-K | 2026-09-16 | View on SEC.gov → |
| 2026-09-09 | 8-K | 2026-09-09 | View on SEC.gov → |
| 2026-08-21 | 8-K | 2026-08-20 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-05 | 4 | 2026-05-01 | View on SEC.gov → |
| 2026-05-05 | 4 | 2026-05-01 | View on SEC.gov → |
| 2026-05-05 | 4 | 2026-05-01 | View on SEC.gov → |
| 2026-05-05 | 4 | 2026-05-01 | View on SEC.gov → |
| 2026-05-05 | 4 | 2026-05-01 | View on SEC.gov → |
| 2026-05-05 | 4 | 2026-05-01 | View on SEC.gov → |
Recent news
Headlines about KTTA (Pasithea Therapeutics Corp.). Links open the publisher — we don’t host full articles.
-
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Yahoo Finance · 2026-09-14 -
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Yahoo Finance · 2026-07-21 -
New Strong Buy Stocks for July 20th
Yahoo Finance · 2026-07-20 -
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Yahoo Finance · 2026-07-08 -
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Yahoo Finance · 2026-06-30 -
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
Yahoo Finance · 2026-06-15 -
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Yahoo Finance · 2026-06-10 -
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Yahoo Finance · 2026-06-02
No headlines in this category right now — try “All”.